News und Analysen

Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in

Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in

Regulatory News:

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s (Paris:TNG) proprietary DuckCelt®-T17 cell line.

Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.

First quarter 2020 results:

• 
  Revenue of $859 million, a 2% increase compared to

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.

First quarter 2020 results:

• 
  Revenue of $859 million, a 2% increase compared to

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.

First quarter 2020 results:

• 
  Revenue of $859 million, a 2% increase compared to

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital therapeutics, have

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2020, highlighting revenue growth and financial strength, clinical pipeline developments and the company’s

The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), today announced it will deploy $50 million in immediate short-term and long-term relief and partner with national and community

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday

Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)

Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)

Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.

For the first quarter of 2020, worldwide sales

Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports its cash position as of 31 March

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23^rd Annual Meeting of the American Society of

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2020.

First Quarter 2020 and COVID-19 Pandemic Response Highlights:

• 
  Revenue grew 44%